Editorial

Incretin therapies have emerged as a promising treatment option with potential benefits for mitigating cardiometabolic side effects associated with antipsychotics; however, clinical trials have often excluded psychiatric populations.

The authors of a new review argue that depression and obesity fuel each other in a brutal feedback loop that must be treated together.